Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome binding/occupancy profiling of HIF and AHR in RCC4 cells under co-activating conditions

ABSTRACT: Genome binding/occupancy profiling of HIF and AHR in RCC4 cells under co-activating conditions

PROVIDER: PRJNA848816 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RCC4/VHL cells under HIF and AHR co-activating conditions

Project description:RCC4/VHL cells under HIF and AHR co-activating conditions

| PRJNA848815 | ENA

Genome binding/occupancy profiling of HIF and AHR in RCC4 cells under co-activating conditions

Project description:ChIP-seq analysis of HIF-1, HIF-2 and AHR DNA binding under single and combined activating conditions

2023-01-24 | GSE206028 | GEO

Expression profiling in RCC4/VHL cells under HIF and AHR co-activating conditions

Project description:Pan-genomic analysis of poly-adenylated transcript levels under HIF and AHR single and combined activating conditions

2023-01-24 | GSE206027 | GEO

Expression profiling in RCC4/VHL cells under HIF and AHR co-activating conditions

Project description:Expression profiling in RCC4/VHL cells under HIF and AHR co-activating conditions

| PRJNA848810 | ENA

RCC4/VHL cells under HIF and AHR co-activating conditions

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-01-24 | GSE206029 | GEO

Effect of depletion of MIRE on gene expression of RCC4 cells.

Project description:To investigate the effect of depletion of MIRE on gene expression of RCC4 cells. We then performed gene expression profiling analysis using data obtained from RNA-seq.

2023-05-24 | GSE218179 | GEO

Expression profile of RCC4 cells with YAP silencing

Project description:YAP is the one of the effectors of Hippo pathway. YAP promotes organ size growth as well as tumor metastasis. In this study, YAP is silencing in clear cell carcinoma cell line RCC4 to elucidate the downstream targets that promotes the resisntance toward erastin-induced ferroptosis.

2020-03-05 | GSE146354 | GEO

ZNF207-YWHAZ Enhances Breast Cancer Proliferation and Chemotherapy Resistance by Activating the HIF-1alpha-PPARgamma-PKM2 Signaling Axis.

Project description:Hypoxia is closely linked to chemotherapy resistance and accelerates breast cancer progression. However, the underlying mechanism of resistance to hypoxic chemotherapy remains uncertain. ZNF207 was identified as a differentially expressed gene involved in hypoxia and chemotherapy resistance by RNA-sequencing array. ZNF207 expression was elevated in lung, breast, liver, colon, and ovarian cancers, and its positive expression was correlated significantly with advanced TNM stage, lymph node metastasis, and poor prognosis. ZNF207 overexpression promoted the proliferation, invasion capabilities, and stemness of breast cancer cells by activating the HIF-1alpha-PPAR-gamma-glycolysis signaling pathway. Notably, ZNF207 was directly bound to the coiled-coil domain of YWHAZ, thereby accelerating HIF-1alpha deacetylation in an HDAC4-dependent manner. Furthermore, ZNF207 might stabilize YWHAZ by inhibiting its degradation via TRIM67 through a ubiquitin-dependent mechanism. ZNF207 overexpression enhanced resistance to doxorubicin and vinorelbine. Conversely, ZNF207-DeltaGLE overexpression disrupted HIF-1alpha-PPAR-gamma-glycolysis signaling and abolished chemotherapy resistance. Additionally, ZNF207 expression was higher in patients with breast cancer who exhibited poor treatment outcomes (Miller/Payne grades 1-2) than in those with more favorable outcomes (Miller/Payne grades 3-5). Sappanchalcone, a specific ZNF207 inhibitor, impedes breast cancer progression while exerting a synergistic effect with chemotherapy. Our findings revealed that ZNF207 expression was elevated in breast cancer under hypoxic conditions, promoting proliferation and invasion by activating HIF-1alpha through accelerated deacetylation in a positive feedback loop. The interaction between ZNF207 and YWHAZ enhances HIF-1alpha stability, ultimately accelerating therapeutic resistance in breast cancer.

2024-10-16 | GSE279294 | GEO

ZNF207-YWHAZ Enhances Breast Cancer Proliferation and Chemotherapy Resistance by Activating the HIF-1alpha-PPARgamma-PKM2 Signaling Axis

2024-10-21 | GSE279443 | GEO

Rutaecarpine inhibits glioblastoma migration by activating the aryl hydrocarbon receptor (AhR) signaling pathway

Project description:Glioblastoma is the most frequent and aggressive primary astrocytoma in adults. The high migration ability of the tumor cells is an important reason for the high recurrence rate and poor prognosis of glioblastoma. Recently, emerging evidence has shown that the migration ability of glioblastoma cell was inhibited upon the activation of aryl hydrocarbon receptor (AhR), suggesting potential anti-tumor effects of AhR agonists. Rutaecarpine is a natural compound with potential tumor therapeutic effects which can possibly bind to AhR. However, its effect on the migration of glioblastoma is unclear. Therefore, we aim to explore the effects of rutaecarpine on the migration of human glioblastoma cells U87 and the involvements of the AhR signaling pathway. The results showed that: (i) compared with other structural related alkaloids, like evodiamine and dehydroevodiamine, rutaecarpine was a more potent AhR activator, and has stronger inhibitory effect on the glioblastoma cell migration; (ii) rutaecarpine decreased the migration ability of U87 cells in an AhR-dependent manner; (iii) AhR mediated the expression of a tumor suppressor interleukin 24 (IL24) induced by rutaecarpine, and AhR-IL24 axis was involved in the anti-migratoryeffects of rutaecarpine on the glioblastoma. Besides IL24, other motility related genes were proposed to participate in the migration regulation process of rutaecarpine by RNA-Seq analysis. These data suggest that rutaecarpine is a natural AhR agonist that could inhibit the migration of glioblastomaandbe a potential candidate for developing therapeutic drug against glioblatoma.

2021-12-07 | GSE183606 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data